These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1449 related articles for article (PubMed ID: 33937333)

  • 1. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
    Li P; Lu Z; Li Q; Wang Z; Guo Y; Cai C; Wang S; Liu P; Su X; Huang Y; Dong Y; Qiu W; Ling Y; Yarmus L; Luo F; Zeng L; Bai C; Zhang W
    Front Mol Biosci; 2021; 8():651662. PubMed ID: 33937333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
    Wang Y; Chen Y; Zhou X
    Can J Infect Dis Med Microbiol; 2022; 2022():6375870. PubMed ID: 35308307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study.
    Kardos Z; Szabó M; Baráth Z; Miksi Á; Oláh C; Kozma Á; Gergely JA; Csánky E; Szekanecz Z
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830885
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia.
    Milošević I; Barać A; Jovanović J; Vujović A; Stevanović G; Todorović N; Milošević B
    Trans R Soc Trop Med Hyg; 2023 Sep; 117(9):668-672. PubMed ID: 37103332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of tocilizumab treatment among a cohort of patients with COVID-19 infection from Western India.
    Surana PD; Nayak R; Sheikh A; Haldankar P; Kale J
    J Family Med Prim Care; 2022 Jan; 11(1):123-132. PubMed ID: 35309657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
    Bhandari S; Rankawat G; Singh A
    Indian J Crit Care Med; 2021 Mar; 25(3):260-266. PubMed ID: 33790504
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study.
    Zarębska-Michaluk D; Jaroszewicz J; Rogalska M; Martonik D; Pabjan P; Berkan-Kawińska A; Bolewska B; Oczko-Grzesik B; Kozielewicz D; Tudrujek-Zdunek M; Kowalska J; Moniuszko-Malinowska A; Kłos K; Rorat M; Leszczyński P; Piekarska A; Polańska J; Flisiak R
    J Inflamm Res; 2021; 14():3359-3366. PubMed ID: 34295173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.
    Gao Q; Yin X; Tan B; Wang J; Chen J; Zhao B; Yang Q; Li Z
    BMC Infect Dis; 2022 Dec; 22(1):929. PubMed ID: 36503381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6.
    Ponthieux F; Dauby N; Maillart E; Fils JF; Smet J; Claus M; Besse-Hammer T; Bels D; Corazza F; Nagant C
    Viral Immunol; 2022; 35(1):60-70. PubMed ID: 35085462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early tocilizumab treatment was associated with survival benefits in hospitalized kidney transplants with severe COVID-19 infection: A prospective cohort study.
    Tang Y; Yin S; Zhang H; Wu L; Fan Y; Lin T; Song T
    Transpl Immunol; 2024 Dec; 87():102110. PubMed ID: 39218267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients.
    Abdel-Salam Elgohary M; Ali A; J Alarfaj S; Shahin H; Ibrahim Zaki A; Medhat Hasan E; Emam Mohamed M; Mahmoud Elkholy A; El-Masry TA; Samir Kamal J; Ali AbdelRahim M; Wageh Saber A; Seadawy MG; Elshishtawy MHM; El-Bouseary MM
    Cytokine; 2024 Jan; 173():156433. PubMed ID: 37972479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab and COVID-19: Timing of administration assessment.
    Richier Q; Jachiet V; Bonnemains V; Plaçais L; Abisror N; Garnier M; Pacanowski J; Dhote R; Hinchschberger O; Michel M; Bienvenu B; Comarmond C; Lacombe K; Mekinian A
    Infect Dis Now; 2022 Feb; 52(1):31-34. PubMed ID: 34198000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early use of tocilizumab in hospitalized patients with severe and critical COVID-19 in the Province of Buenos Aires: a multicentric study].
    Salazar M; Varela Baino AN; González S; González Martínez V; Varela T; Regairaz L; Torres K; Kreplak N; Estenssoro E
    Medicina (B Aires); 2023; 83(2):190-201. PubMed ID: 37094187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study.
    Hafez W; Ziade MA; Arya A; Saleh H; Abdelshakor M; Fadl Alla O; Agrawal P; Ali S; Rao SR; Gupta S; Abdelli I; Sebastian H; Ali M; Gador M; Al Baha Z; Abdelrahman A
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate Use of Tocilizumab in COVID-19: Early Use is Beneficial.
    Altunal LN; Aydın M; Özel AS; Çam G
    Infect Dis Clin Microbiol; 2022 Jun; 4(2):116-121. PubMed ID: 38633336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
    Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
    Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
    Fomina DS; Lysenko MA; Beloglazova IP; Mutovina ZY; Poteshkina NG; Samsonova IV; Kruglova TS; Chernov AA; Karaulov AV
    Pathog Immun; 2020; 5(1):327-341. PubMed ID: 33089038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.